HENRY JEMIL ESBER
CIK 1391501 · EVP Pre-Clinical Business Dev. · last filed 2019-07-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$520.7K
Companies
3
Total Filings
39
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SEELOS THERAPEUTICS, INC. (APRI) Delisted | Director | 35,492 | — | — | $0 | 4 | 2012-01-04 |
| NEXM | EVP Pre-Clinical Business Dev. | 220,656 | $2.36 | $520.7K | $0 | 3 | 2010-04-13 |
| GALECTIN THERAPEUTICS INC (PRW) Delisted | Director | — | — | — | $0 | 2 | 2008-03-17 |
Recent Filings · Page 3 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-04-01 | — | Grant (A) | — | $0 | |
| 2015-03-20 | — | Mixed | +9,000 | $1.8K | |
| 2015-01-06 | — | Grant (A) | +37,500 | $0 | |
| 2014-10-03 | — | Grant (A) | +16,216 | $0 | |
| 2014-07-03 | — | Grant (A) | +22,222 | $0 | |
| 2014-02-20 | — | Conv (C) | +228,268 | $0 | |
| 2014-02-06 | — | Grant (A) | +15,000 | $0 | |
| 2013-10-18 | — | Grant (A) | +3,750 | $0 | |
| 2012-01-04 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +2,505 | $12.9K | EDGAR |
| 2011-10-04 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Mixed | +62,835 | $9.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.